Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of ABP 938 versus Eylea in neovascular age-related macular degeneration
2019-002503-17Phase 3Completed
- Sponsor
- Amgen
- Start
- Jan 2020
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of 9MW0813 in exudative macular degeneration (2 arms), sponsored by Amgen. Primary endpoint: Change from baseline in best corrected visual acuity (BCVA) at week 8. Started Jan 2020; status: completed.
02
Drugs
9MW0813
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2019-002503-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002503-17.